Page last updated: 2024-12-05

norbormide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

norbormide: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12399560
SCHEMBL ID436736
MeSH IDM0046805

Synonyms (10)

Synonym
mcn 1025
s 6999
raticate
shoxin
norbormide
991-42-4
SCHEMBL436736
(10e)-8-[hydroxy(phenyl)pyridin-2-ylmethyl]-10-[phenyl(pyridin-2-yl)methylidene]-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione
Q7050437
AKOS040746163

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects."( Design and synthesis of prodrugs of the rat selective toxicant norbormide.
Bova, S; Brimble, MA; Cavalli, M; Hopkins, B; Laita, O; Linthicum, DS; Rennison, D, 2012
)
0.38
" However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects."( Prodrugs of N-dicarboximide derivatives of the rat selective toxicant norbormide.
Bova, S; Brimble, MA; Cavalli, M; Conole, D; Hopkins, B; Jay-Smith, M; Knauf, J; Laita, O; Linthicum, DS; Rennison, D, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (13.04)18.7374
1990's2 (8.70)18.2507
2000's11 (47.83)29.6817
2010's5 (21.74)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies1 (4.17%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]